Result as attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Choksi Laboratories reported revenue from operations of ₹4,600.59 lakhs for FY2026, up 10.1% from ₹4,178.23 lakhs in FY2025. Net profit after tax grew 28.9% to ₹196.43 lakhs from ₹152.33 lakhs. EBITDA from operations was ₹244.16 lakhs vs ₹215.33 lakhs, with EBITDA margin expanding marginally from 5.14% to 5.28%. The company sold an office flat during Q4 generating an exceptional gain of ₹75.30 lakhs. The statutory auditor issued an unqualified opinion with no modifications. Long-term borrowings increased significantly to ₹1,780.99 lakhs from ₹1,523.36 lakhs. Operating cash flow remained positive at ₹786.48 lakhs though lower than the previous year's ₹1,177.80 lakhs.
The company delivered healthy profit growth of nearly 29% with stable margins, but the significant increase in debt and lower operating cash flow are concerns. The one-time exceptional gain from property sale boosted reported profits. Shareholders should note the auditor raised no concerns.